Instil Bio
R. Kent McGaughy, Jr. is a founding shareholder of CPMG, Inc. Prior to joining CPMG’s predecessor, Cardinal Investment Company, in 1997, Mr. McGaughy worked in investment banking at Simmons & Company International. Mr. McGaughy serves as a Director of Reata Pharmaceuticals (NASDAQ: RETA), Apollo Endosurgery (NASDAQ: APEN), Cuda Pharmaceuticals LLC, Waterfall Security Solutions, Ltd. and Instil Bio, Inc. Mr. McGaughy holds a B.A. from The University of Texas (Plan II Honors, Summa Cum Laude, and member of Phi Beta Kappa) and an M.B.A. from Harvard Business School.
This person is not in the org chart
This person is not in any offices
Instil Bio
1 followers
Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient’s own T cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. The company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered TIL. The company is led by world-class cell therapy experts and backed by premier global institutional investors. Instil is located in the greater Los Angeles area with additional manufacturing and research facilities in Manchester, UK.